Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Adv. 2025 May 27; 9(10):2453-2457.
PMID: 39969200
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025 May 22.
PMID: 40400334
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Mar 14.
PMID: 40085959
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study. Am J Hematol. 2025 Jun; 100(6):1082-1085.
PMID: 40062542
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2025 Feb 16.
PMID: 40050145
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
PMID: 39866945
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax?+?Hypomethylating Agent.
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax?+?Hypomethylating Agent. Am J Hematol. 2025 Feb; 100(2):260-271.
PMID: 39671248
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
PMID: 39250708
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms.
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.
PMID: 39551719
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
PMID: 38996210